In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard therapy for patients with chronic lymphocytic leukemia (CLL) who have ...
Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...
Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment ...
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitor selection in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) depends on key factors including prior therapy ...
Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...
Pirtobrutinib combination therapy significantly improves progression free survival vs venetoclax and rituximab in relapsed or refractory CLL/SLL. Topline data were announced from a phase 3 trial ...
Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated approval to rocbrutinib (development code: LP-168) for the treatment of adult ...
Researchers review available clinical evidence for retreatment with venetoclax, alone or in combination, in patients with relapsed chronic lymphocytic leukemia.
Nurix Therapeutics, Inc. has announced that data from its ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) will be presented at two major scientific conferences. The trial focuses on ...
Eli Lilly and Company (NYSE: LLY) today announced the details of presentations at the European Hematology Association (EHA) ...
Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...
At a median duration of follow-up of 6.6 months, treatment with pirtobrutinib reduced the risk of progression or death by 42%. The Food and Drug Administration (FDA) has approved Jaypirca ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results